A Breakthrough in TB Diagnostics

Our breakthrough biophotonic detection platform utilizes Reporter Enzyme Fluorescence to detect live TB bacteria. The technology offers the potential to increase the sensitivity of detection by orders of magnitude over current widely available diagnostics in endemic settings. Through a Co-Development partnership with the Foundation for Innovative New Diagnostics (FIND), we are developing our GBD μ-Lab™ POC-F diagnostic assay that offers the potential to be the world’s first true Point-of-Care TB diagnostic. Learn More

Our Philosophy

• Constraint Based Innovation
  Designing for the needs of resource constrained environments.
• Collaborative Partnerships
  Working with experts in global health to inform design of products that are low-cost, easy-to-use and rapid.
• Global Thinking
  Leveraging available resources on a global basis to maximize efficiency.
Learn More

Our Partners